No Data
No Data
EMVision Medical Devices' Interim Trial Data Shows Promising Results in Identifying Stroke Types
Stage 2 interim data from a pre-validation trial by EMVision Medical Devices (ASX: EMV) has confirmed the positive performance of neurodiagnostic artificial intelligence (AI) algorithms in the diagnosis of suspected haemorrhagic or ischaemic strokes.
EMvision Medical Devices Verifies Stroke Detection of Algorithm Technology
EMvision Medical Devices (ASX:EMV) verified the stroke detection of its algorithm technology underpinning its EMVision brain scanner device following interim results from a stage two pre-validation cl
EMVision Medical Devices Ltd's (ASX:EMV) Largest Shareholders Are Retail Investors With 54% Ownership, Insiders Own 23%
EMVision Medical Devices Secures AU$15.28 Million Investment From Keysight Technologies
EMVision Medical Devices (ASX:EMV) secured an investment worth AU$15.3 million via a placement to California-based technology company Keysight Technologies (NYSE:KEYS), according to a Thursday release
EMVision Medical Devices Secures Nearly AU$3 Million R&D Tax Rebate for Fiscal Year 2023
EMVision Medical Devices (ASX:EMV) secured a AU$2.6 million tax rebate for the fiscal year ended June 30 from the Australian government's research and development tax incentive scheme, according to a
EMVision Medical Devices Enrolls 150 Patients for Brain Scanner Trials
EMVision Medical Devices (ASX:EMV) said it has enrolled 150 suspected stroke patients for Stage II of the firm's Australian clinical trials of its new point-of-care brain scanner, named 'emu'. In para
No Data